Dr. Zhao Piming, founder and CEO of Taogen Bio, is a leading talent in gene therapy innovation. He holds a bachelor's degree from Lanzhou University and a PhD in molecular genetics from the Institute of Microbiology, Chinese Academy of Sciences. He has conducted postdoctoral research at Loyola University Medical Center in Chicago and UCSF, serving as a senior scientist in gene therapy. With 16 years of experience in gene therapy and translational medicine, he led the world's first gene therapy project for chronic kidney disease (SPLIS), obtained a US gene therapy patent, and promoted related small molecule research, benefiting patients in Singapore, Pakistan, and other places. He excels in building platform capabilities and creating high-value pipelines, and is committed to making cutting-edge gene therapy accessible and affordable. He has won the "New Drug Development Scientist Award" at the 7th CMC-CHINA in 2025. He is a member of AHA/APS, a part-time mentor at the School of Pharmacy, Soochow University, and a leading entrepreneur in Suzhou Industrial Park.